July 20, 2020
Liid Pharmaceuticals, a biotech established by researchers at the National Cerebral and Cardiovascular Center (NCVC), is aiming to launch a first-in-human (FIH) clinical trial in FY2022 for its lead hypertriglyceridemia drug candidate. With the company now in talks with a...read more